A Multianalyte Assay Panel With Cell‐Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology–Classified Lupus

Abstract

Objective To evaluate the usefulness of biomarkers to predict the evolution of patients suspected of systemic lupus erythematosus (SLE), designated as probable SLE (pSLE), into classifiable SLE according to the American College of Rheumatology (ACR) classification criteria. Methods Patients suspected of SLE were enrolled by lupus experts if they fulfilled three ACR criteria for SLE and were followed for approximately 1‐3 years to evaluate transition into ACR‐classifiable SLE. Individual cell‐bound complement activation products (CB‐CAPs), serum complement proteins (C3 and C4), and autoantibodies were measured by flow cytometry, turbidimetry, and enzyme‐linked immunosorbent assay, respectively. Blood levels of hydroxychloroquine (HCQ) were measured by mass spectrometry. A multianalyte assay panel (MAP), which includes CB‐CAPs, was also evaluated. A MAP of greater than 0.8 reflected the optimal cutoff for transition to SLE. Time to fulfillment of ACR criteria was evaluated by Kaplan‐Meier analysis and Cox proportional hazards model. Results Of the 92 patients with pSLE enrolled, 74 had one or two follow‐up visits 9‐35 months after enrollment for a total of 128 follow‐up visits. Overall, 28 patients with pSLE (30.4%) transitioned to ACR‐classifiable SLE, including 16 (57%) in the first year and 12 (43%) afterwards. A MAP score of greater than 0.8 at enrollment predicted transition to classifiable SLE during the follow‐up period (hazard ratio = 2.72; P = 0.012), whereas individual biomarkers or fulfillment of Systemic Lupus International Collaborating Clinics criteria did not. HCQ therapy was not associated with the prevention of transition to SLE. Conclusion Approximately one‐third of patients with pSLE transitioned within the study period. MAP of greater than 0.8 predicted disease evolution into classifiable SLE.

Disease criteria of systemic lupus erythematosus (SLE); the potential role of non-criteria autoantibodies

“…Complement activation, identified as low levels of C3, C4 or CH50 in the EULAR/ACR 2019 classification criteria for SLE, is very important in pathogenesis of SLE, together with the presence of autoantibodies, and the measurement of such activation is relevant. Very recently, the addition of measurement of cell-bound activation products by flow cytometry has demonstrated to predict the transition from probable lupus to EULAR/ACR 2019 classification criteria better than classical autoantibodies in a 78 patients cohort [ 125 ].…”

The Rise and Rise of Lupus

“…In contrast, traditional biomarkers (complement levels and anti-dsDNA) and an EC4d value greater than 20 mean fluorescence intensity did not predict transition, indicating that a panel performs better than any individual biomarker. 77 Early SLE (incomplete lupus)…”

Use of Beet Root for Culturing Gram Negative Bacteria in Laboratory

“…A biomarker is a measurable indicator of a normal biological function, pathogenic activity, or a response to medicine or intervention (Szefler et al, 2012;Ramsey-Goldman et al, 2021). Biomarkers it has recently been redefined to include a distinguishing physical sign or cellular, biochemical, molecular, or genetic feature, as well as the ability to recognize and/or observe a biologic process or morbid condition using a qualitative and/or quantitative test (González, Ugarte-Gil, and Alarcón 2021).…”